Try our mobile app

Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC

Published: 2022-06-06 13:00:00 ET
<<<  go to GILD company page

Trodelvy Also Reduced the Risk of Disease Progression or Death by 59% Compared to Physicians’ Choice of Chemotherapy

CHICAGO--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today presented final data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) in patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies, at least one of them for metastatic disease. In a follow-up analysis from the final database lock, Trodelvy improved median progression-free survival versus physicians’ choice of chemotherapy (4.8 vs. 1.7 months; HR: 0.41; p